Compare
Palvella Therapeutics, Inc. vs ProPhase Labs, Inc. vs ALX Oncology Holdings Inc vs Scynexis Inc
| Latest fiscal year | Palvella Therapeutics, Inc. PVLA | ProPhase Labs, Inc. PRPH | ALX Oncology Holdings Inc ALXO | Scynexis Inc SCYX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $4.34M | n/a | $20.60M |
| Revenue growth (YoY) | n/a | -35.8% | n/a | +449.9% |
| Gross margin | n/a | 31.9% | n/a | n/a |
| Operating margin | n/a | -415.4% | n/a | -78.0% |
| Net margin | n/a | -339.3% | n/a | -41.8% |
| Net income | -$41.72M | -$14.74M | -$101.69M | -$8.61M |
| EPS (Diluted) | -$3.71 | -$1.74 | -$1.90 | -$0.17 |
| Operating cash flow | -$25.01M | -$8.34M | -$84.14M | -$5.28M |
| Free cash flow | n/a | -$8.34M | -$84.35M | n/a |
| Cash & equivalents | $57.98M | $90.0K | $16.37M | $21.26M |
| Total assets | $59.56M | $59.87M | $59.05M | $59.03M |
| Total liabilities | $31.58M | $56.36M | $33.06M | $9.65M |
| Shareholders' equity | $27.98M | $3.51M | $25.98M | $49.38M |
| Return on year-end equity | -149.1% | -420.3% | -391.4% | -17.4% |
| Shares outstanding | 12.38M | 8.97M | 54.39M | 43.54M |
Revenue, most recent five fiscal years
| Fiscal year | Palvella Therapeutics, Inc. | ProPhase Labs, Inc. | ALX Oncology Holdings Inc | Scynexis Inc |
|---|---|---|---|---|
| Latest | $42.81M Ended 2023-12-31 | $4.34M Ended 2025-12-31 | $0 Ended 2022-12-31 | $20.60M Ended 2025-12-31 |
| 1 year earlier | $25.90M Ended 2022-12-31 | $6.77M Ended 2024-12-31 | $0 Ended 2021-12-31 | $3.75M Ended 2024-12-31 |
| 2 years earlier | $31.42M Ended 2021-12-31 | $34.98M Ended 2023-12-31 | $1.18M Ended 2020-12-31 | $140.14M Ended 2023-12-31 |
| 3 years earlier | $29.32M Ended 2020-12-31 | $122.65M Ended 2022-12-31 | $4.80M Ended 2019-12-31 | $5.09M Ended 2022-12-31 |
| 4 years earlier | $46.28M Ended 2019-12-31 | $79.04M Ended 2021-12-31 | $2.07M Ended 2018-12-31 | $13.16M Ended 2021-12-31 |